Proactive Investors - Run By Investors For Investors

Adamis Pharmaceuticals shares skyrocket on news of Novartis distribution deal for anaphylaxis product

The deal is with the Sandoz Inc division is for the Adamis’ Symjepi product
Adamis Pharmaceuticals shares skyrocket on news of Novartis distribution deal for anaphylaxis product
Adamis’ Symjepi product is for the emergency treatment of allergic reactions

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares shot up almost 40% to US$4.45 on Monday after the San Diego-headquartered firm after it announced a distribution and commercialization agreement with drugs giant Novartis Group.

The deal with the latter's Sandoz Inc division is for the  Adamis’ Symjepi product for the emergency treatment of allergic reactions (Type I) including anaphylaxis.

The Symjepi injector is a competitor of Mylan's well-known EpiPen product

Sandoz will distribute and sell the 0.3 and 0.15 mg versions of Symjepi, said Adamis.

"We are very excited about our collaboration with Sandoz," said Dr Dennis J. Carlo, the president and chief executive of Adamis.

"They are among the top pharmaceutical companies in the world and we believe they have the commercial presence and proven track record to maximize the value of Symjepi. 

"We believe the financial terms of this agreement have the potential to bring meaningful recurring revenue to Adamis and we look forward to growing, and possibly expanding, this partnership with Sandoz based on the future success of Symjepi in the market.”

Adamis is a specialty biopharma company, which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.

View full NVS profile View Profile

Novartis Timeline

Related Articles

scientist in lab
December 20 2018
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Oncoprex
October 18 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use